News & Events
You are here
NOVOTECH CRO EXPANDS ASIA REGION SERVICES WITH NEW CHINA OFFICE IN SHANGHAI
Australia’s largest clinical CRO with offices throughout Asia, announced today the expansion of services to China with a Novotech office in Shanghai, a wholly owned entity with local staff...
Clinical Trials in Asia – 10 Years on
In 2004, I authored an article entitled “Clinical Trials in Asia: A Promising Picture” on the potential of Asia as a significant contributor to global clinical drug development. The article was published in the Ernst and Young Annual Global...
NOVOTECH CRO ANNOUNCES MOU WITH KOREA DRUG DEVELOPMENT FUND (KDDF) AT DIA 2014
San Diego, CA, June 15, 2014 | Novotech, Australia’s largest clinical CRO with offices throughout Asia, has signed an MOU with the Korea Drug Development Fund (KDDF) to promote the development of the Korean biotechnology sector in the Asia...
Considerations for Asia Pacific clinical trials
As in many other industries, the emerging markets of Asia represent new frontiers for pharmaceutical and biotechnology companies. In recent years the widespread adoption of GCP across the region has meant the industry now is looking to Asia not...
Asian Century and clinical trials: Issues for consideration by biotechnology companies
As with many other industries, there is a prevailing belief that the 21st Century will be the Asian Century when it comes to drug development and the pharmaceutical industry. Already, markets such as China are predicted to overtake the US to...
Australian CRO Novotech announces expanded Asia reach into Hong Kong and Philippines at DIA 2013
Sydney, Australia, 23 June, 2013 – Novotech, Australia’s largest clinical CRO has expanded its Asia reach into Hong Kong and the Philippines, building on its established network which already includes a presence in Singapore, South Korea, Taiwan...
Experienced Australian CRO attains Medidata accreditation to offer enhanced clinical trial services
Novotech has expanded its relationship with Medidata Solutions (NASDAQ:MDSO) by achieving accreditation for Medidata Rave®, an industry leading system for electronic data capture (EDC) and clinical data management (CDM).
Novotech CRO attracts investment for Asia Clinical Trial expansion
Sydney, Australia, 6 May, 2013 – Novotech, Australia’s largest independent
CRO today announced a funding injection from private equity firm Mercury
Capital - ...
Alchemia Recruits Full Patient Quota to Pivotal Phase III HAIrinotecan Trial in Metastatic Colorectal Cancer
Brisbane-based drug discovery and development company Alchemia Limited (ASX: ACL) has recruited the 390th patient to its pivotal Phase III clinical trial
of the Company’s lead cancer drug, HA-Irinotecan, as per its study protocol.
The Road Less Travelled – Navigation through the do’s and don’ts of running Oncology studies in Asia Pacific
Clinical trials in the Asia Pacific are increasing exponentially. Numerous sponsors and CROs have accessed this region in recent years to take advantage of high performing, cost effective sites.